Diclazuril
Associated AOPs with Level of Relevance - 1 AOPs with at least 1 KE associated with chemical, where the KE(s) are neither MIE nor AO
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1154 | Increased, Triiodothyronine (T3) in tissues |
| KE:1829 | Altered, Thyroid hormone-dependent gene expression |
No associated AOPs with Level of Relevance 2
Associated AOPs with Level of Relevance - 3 AOPs with at least 1 MIE associated with chemical, and no associated AO
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:1656 | Antagonism, Thyroid Receptor |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:1656 | Antagonism, Thyroid Receptor |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | | 0.15 | KE:2216 | Binding of antagonist to thyroid hormone receptor |
| KE:1656 | Antagonism, Thyroid Receptor |
No associated AOPs with Level of Relevance 5
DISCLAIMER
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.